Wasdell makes multimillion-pound investment in new packaging equipment
The contract packaging company has plans to install new equipment for the company’s blister and bottle lines, vial labelling, stability chambers and cold storage capacity.
Wasdell Group, a pharmaceutical outsourcing partner, has confirmed it is making a multimillion-pound investment in new packaging equipment across its UK and Ireland sites.
The specialist in end-to-end supply chain service provider made the decision to invest in line with increasing demand for its manufacturing and packaging capabilities from its growing pharma and biotech client portfolio.
The investment, which is part of a long-term investment plan to expand the company's capacity and capabilities, includes equipment for the company’s blister and bottle lines, vial labelling, stability chambers and cold storage capacity.
The equipment will be installed across all Wasdell’s sites in the UK and Ireland, including the recently opened Dundalk facility.
In addition to meeting increased demand, Vincent Dunne, CEO at Wasdell, explained the company's new packaging equipment will "allow us to maintain the swift turnaround times and flexible service we are well known for in the industry".
According to Martin Tedham, Wasdell Group Chairman, the investment will also support the company's expanding customer base, particularly US life sciences companies that want to "source a provider that can readily navigate the European market and specialises in small-mid batch sizes.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.